The Effect of Insulin Glulisine Compared With Insulin Aspart on Breakfast Post Prandial Glucose Levels in Prepubertal Children
The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2009 by Spectrum Health Hospitals.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Spectrum Health Hospitals
Collaborator:
Helen DeVos Children's Hospital
Information provided by:
Spectrum Health Hospitals
ClinicalTrials.gov Identifier:
NCT00913497
First received: June 2, 2009
Last updated: December 29, 2009
Last verified: December 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To determine whether insulin glulisine decreases the breakfast post prandial glycemic excursion in comparison to insulin aspart.
| Condition | Intervention | Phase |
|---|---|---|
|
Type 1 Diabetes Mellitus |
Drug: insulin glulisine Drug: insulin aspart |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Bio-equivalence Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase 4 Crossover Study Comparing the Effect of Insulin Glulisine to Insulin Aspart on Breakfast Post Prandial Blood Glucose Levels in Prepubertal Children With Type 1 Diabetes Mellitus on Multiple Daily Insulin Injection Therapy |
Resource links provided by NLM:
Further study details as provided by Spectrum Health Hospitals:
Primary Outcome Measures:
- Difference in the two hour and four hour post prandial blood glucose levels following administration of insulin glulisine versus insulin aspart at the end of the twenty study days [ Time Frame: 45 days ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Incidence of symptomatic hypoglycemia; hyperglycemia with ketonuria; systemic allergic reactions; localized injection site reactions [ Time Frame: 45 days ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 24 |
| Study Start Date: | June 2009 |
| Estimated Study Completion Date: | November 2010 |
| Estimated Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: insulin glulisine |
Drug: insulin glulisine
Insulin glulisine (Apidra®) Sanofi-Aventis; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days
Other Name: (Apidra®)
|
| Active Comparator: insulin aspart |
Drug: insulin aspart
Insulin aspart (NovoLog®) Novo Nordisk; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days.
Other Name: (NovoLog®)
|
Detailed Description:
This is a treatment, open label, crossover study comparing two and four hour breakfast post prandial blood glucose levels after receiving a dose of insulin glulisine or insulin aspart administered subcutaneously and consuming the breakfast meal from a prescribed menu containing 45, 60 or 75 grams of carbohydrate. Each subject will receive insulin glulisine for ten days and insulin aspart for ten days.
Eligibility| Ages Eligible for Study: | 4 Years to 11 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- current patient in the Helen DeVos Children's Hospital Diabetes Clinic;
- ages 4-11 years;
- prepubertal (Tanner Stage I);
- diagnosed with type 1 diabetes mellitus with positive islet cell antibodies or presenting at time of diagnosis with positive serum or urine ketones and requiring insulin since diagnosis;
- at least six months from date of diagnosis of type 1 diabetes mellitus;
- TSH within reference range and negative transglutaminase IgA antibodies within nine months of study start;
- HbA1C between 6.9 and 10% within 30 days of study start; parent or guardian able and willing to provide written informed consent prior to enrollment;
- at time of study start, current insulin regimen includes multiple daily injections with insulin glargine as the basal insulin and insulin aspart or insulin lispro as the pre-meal rapid acting insulin
Exclusion Criteria:
- pubertal (Tanner stage 2 or greater);
- concurrent Addison's disease, celiac disease or untreated hypothyroidism; - receiving oral, injectable or inhaled steroids or immunosuppressant medications;
- receiving stimulants for treatment of attention deficit disorder or attention deficit hyperactivity disorder;
- intercurrent illnesses such as a fever > 101 degrees F, infection, or gastroenteritis;
- use of any medication to treat diabetes other than those listed under in inclusion criteria;
- potential for lack of compliance or any other issue which, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00913497
Contacts
| Contact: Lora E. Kleis, RN | 616-391-2419 | lora.kleis@devoschildrens.org |
| Contact: Ayse P. Cemeroglu, MD | 616- 391-3933 | ayse.cemeroglu@devoschildrens.org |
Locations
| United States, Michigan | |
| Helen DeVos Childrens Hospital | Recruiting |
| Grand Rapids, Michigan, United States, 49503 | |
| Principal Investigator: Ayse P Cemeroglu, MD | |
Sponsors and Collaborators
Spectrum Health Hospitals
Helen DeVos Children's Hospital
Investigators
| Principal Investigator: | Ayse P Cemeroglu, MD | Helen DeVos Childrens Hospital |
More Information
No publications provided
| Responsible Party: | Ayse Pinar Cemeroglu, MD, Helen DeVos Childrens Hospital |
| ClinicalTrials.gov Identifier: | NCT00913497 History of Changes |
| Other Study ID Numbers: | 2009-089 |
| Study First Received: | June 2, 2009 |
| Last Updated: | December 29, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Spectrum Health Hospitals:
|
Type 1 diabetes mellitus in children insulin glulisine insulin aspart post prandial |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Autoimmune Diseases Immune System Diseases |
Insulin aspart Insulin glulisine Insulin Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 19, 2013